Gene Therapy Market Recent Study Including Growth Factors CAGR of 23.30% by 2027: Applications, Regional Analysis, Key Players

Gene therapy market size is expected at a CAGR of 23.30% during 2021 to 2027. The mushrooming geriatric patient base coupled with the escalating cases of lymphoma and leukemia worldwide will further present attractive opportunities to the major firms in the following years. Escalating cases of target ailments, frequent alliance between the top industry participants and an extensive product pipeline will boost the business growth in subsequent years.

With the disconcerting surge in cancer cases across the globe and a huge patient pool remaining unresponsive to several alternative treatment, the demand for gene therapy has risen considerably over the years. Cancer is a deadly disease that has affected a large portion of the world, inflicting not only the adults but kids as well. The condition entails the use of advanced therapeutic treatments for ensuring the patient’s life quality. Therefore, the soaring focus on developing highly efficient and novel therapies for addressing every symptom will further bolster the gene therapy industry share worldwide in the ensuing years.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/8399

Market Segmentation

Major products discussed in the MRFR review report are Kymriah, Strimvelis, Zynteglo, Imlygic, Luxturna, Zolgensma, Yescarta, and more. Luxturna and Kymriah are the most endorsed products and as a result, have secured the top spot in the global market for gene therapy. Kymriah helps in the treatment of intense lymphoblastic lymphoma, and Luxturna, on the other hand, helps treat retinal dystrophy.

Indication-wise, the key categories can be hereditary illnesses, oncology, and many more. The leading position belongs to the hereditary infections section while the oncology segment shall procure the fastest CAGR in the ensuing years.

Top end-users in the worldwide market are Hospitals & Clinics, Specialty Treatment Centers and others. Given the dramatic rise in the number of hospital and clinics offering advanced medical services and the surge in patient admission rates, the segment is bound to see massive growth over the appraisal period.

Regional Status

With rapid developments in the healthcare sector and soaring number of start-ups, America will emerge as the top market for gene therapy in the next few years. Massive demand for effective medications to treat the surging cases of degenerative disorders should also elevate the market position. The United States can emerge as the top performer in the region over the years ahead, thanks to the well-developed healthcare infrastructure and the significant disposable incomes. Thanks to the robust regulatory framework that promote the creation of advanced cellular therapy along with the vast pool of renowned biopharma companies in the region also adds value to the gene therapy field. The proactive involvement of the government, in terms of large-scale funds, has been favorable as well. With a rising number of players increasingly focusing on taking up strategies, such as acquisitions, mergers, and new launches to enhance their portfolios, the gene therapy industry in the region is touted to see incredible growth in subsequent years. To cite a reference, in October 2021, Sarepta Therapeutics joined hands with Roche to introduce EMBARK, an innovative clinical trial test focused on the investigational gene therapy SRP-9001 for boys affected by Duchenne muscular dystrophy (DMD).

The main growth boosters for the APAC market for gene therapy include the significant improvements in gene therapy as well as the surge in clinical trial activities. Surging prevalence of various chronic ailments, strategic alliances between major vendors, and the rise in private and public initiatives to spread awareness among people will also augment the market position in the years ahead. China is most likely progress at the fastest pace in the APAC market, given the drastic rise in rare disorders and cancer, which have fostered the need for effective gene therapy in the country.

Leading Firms

CEVEC (Germany), Spark Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), Bristol-Myers Squibb Company (US), Amgen, Inc. (US), Celgene Corporation (US), Thermo Fisher Scientific Inc. (US), Novartis AG (Switzerland), Orchard Therapeutics plc (UK), Lonza (Switzerland), uniQure N.V. (Netherlands), are the well-known gene therapy developers highlighted in the MRFR review study.

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/gene-therapy-market-8399

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Tags: Gene Therapy Market Growth, Gene Therapy Market, Gene Therapy Market Research, Gene Therapy Market analysis, Gene Therapy Market Size See Campaign: https://www.marketresearchfuture.com/reports/gene-therapy-market-8399

Contact Information:

Market Research Future (part of Wantstats Research and Media Private Limited), 99 Hudson Street,5Th Floor, New York, New York 10013, United States of America +1 646 845 9312 Email: sales@marketresearchfuture.com

Tags:
PR-Wirein, Wire, Research Newswire, English